Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 77, Issue 1, 2000, Pages 112-115

  Markman, Maurie ^a   Blessing, John A ^b   Alvarez, Ronald D ^c   Hanjani, Parviz ^d   Waggoner, Steven ^e   Hall, Kevin ^f  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER;

EID: 0034006137     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5755     Document Type: Article

References (14)

1. en Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields S C, Heron J F. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 15:1997;2183-2193.
2. Kudelka A P, Tresukosol D, Edwards C L, Freeman R S, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim E E, Madden T, Wallen B, Hord M, Verschraegen C, Raber M, Kavanagh J J. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 14:1996;1552-1557.
3. Creemers G J, Bolis G, Gore M, Scarfone G, Lacave A J, Guastalla J P, Despax R, Favalli G, Kreinberger R, Van Belle S, Hudson I, Verweij J, ten Bokkel Huinink W W. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 14:1996;3056-3061.
4. Swisher E M, Mutch D G, Rader J S, Elbendary A, Herzog T J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 66:1997;480-486.
5. Rowinsky E K, Grochow L B, Hendricks C B, Ettinger D S, Forastiere A A, Hurowitz L A, Mcguire W P, Sartorius S E, Lubejko B G, Kaufmann S H. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol. 10:1992;647-656.
6. Verweij J, Lund B, Beijnen J, Planting A, deBoer-Dennert M, Koier I, Rosing H, Hansen H. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol. 4:1993;673-678.
7. O'Reilly S, Fleming G F, Barker S D, Walczak J R, Bookman M A, McGuire W P 3rd, Schilder R J, Alvarez R D, Armstrong D K, Horowitz I R, Ozol R F, Rowinsky E K. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 15:1997;177-186.
8. Lilenbaum R C, Ratain M J, Miller A A, Hargis J B, Hollis D R, Rosner G I, O'Brien S M, Brewster L, Green M R, Schilsky R L. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B study. J Clin Oncol. 13:1995;2230-2237.
9. Miller A A, Hargis J B, Lilenbaum R C, Fields S Z, Rosner G L, Schilsky R L. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a Cancer and Leukemia Group B study. J Clin Oncol. 12:1994;2743-2750.
10. van Warmerdam L JC, ten Bokkel Huinink W W, Rodenhuis S, Koier I, Davies B E, Rosing H, Maes R A, Beijnen J H. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol. 13:1995;1768-1776.
11. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst. 85:1993;1499-1507.
12. Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 16:1998;2233-2237.
13. Gore M, Rustin G, Calvert H, Bezwodz W, Carmichael J, Oza A, Kaye S, ten Bokkel Huinink W, Malfetano J, Falkson G, Clarke-Pearson D, Ross G A, Dane G C, Fields Z. A multicentre, randomized, phase III study of topotecan administered intravenously or orally for advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol. 17:1998;349a.
14. Creemers G J, Gerrits C JH, Schellens J HM, Planting A S, van der Burg M E, van Geurden V M, de Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G, Verweij J. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol. 14:1996;2540-2545.